Research raises hope for new therapies for chordoma, a rare bone cancer

by Tom Ulrich,Broad Institute of MIT and HarvardCredit: Susanna M. Hamilton, Broad CommunicationsChordoma is literally a one in a million cancer, with few effective treatment options. A new unde

Updated on: May 31,2024

Research raises hope for new therapies for chordoma, a rare bone cancer

by Tom Ulrich,Broad Institute of MIT and HarvardCredit: Susanna M. Hamilton, Broad CommunicationsChordoma is literally a one in a million cancer, with few effective treatment options. A new unde

Updated on:May 31,2024

Actin cytoskeleton remodeling protects tumor cells against immune attack

by Luxembourg Institute of HealthConfocal microscopy image. Accumulation of actin filaments (in green) at the immunological synapse of a resistant cancer cell in contact with an NK cell (in red). Cell

Updated on: December 18,2023

Actin cytoskeleton remodeling protects tumor cells against immune attack

by Luxembourg Institute of HealthConfocal microscopy image. Accumulation of actin filaments (in green) at the immunological synapse of a resistant cancer cell in contact with an NK cell (in red). Cell

Updated on:December 18,2023

Putting a dollar value on cancer survival

by University of the Sunshine CoastCredit: Pixabay/CC0 Public DomainNew University of the Sunshine Coast-led research has for the first time estimated the health care costs of Queenslanders who surviv

Updated on: February 20,2024

Putting a dollar value on cancer survival

by University of the Sunshine CoastCredit: Pixabay/CC0 Public DomainNew University of the Sunshine Coast-led research has for the first time estimated the health care costs of Queenslanders who surviv

Updated on:February 20,2024

The inaugural Sony-Nature Tech Women Award announced, with four winners

Updated on: February 17,2025

The inaugural Sony-Nature Tech Women Award announced, with four winners

Updated on:February 17,2025

FDA approves Abecma for relapsed, refractory multiple myeloma

by Lori SolomonThe U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory multiple myeloma.

Updated on: April 28,2024

FDA approves Abecma for relapsed, refractory multiple myeloma

by Lori SolomonThe U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory multiple myeloma.

Updated on:April 28,2024

Preoperative immunotherapy for mesothelioma shows favorable outcomes

by Dipali Pathak,Baylor College of MedicineCredit: Pixabay/CC0 Public DomainIn a study published recently in the journalClinical Cancer Research, researchers at Baylor College of Medicine

Updated on: January 04,2024

Preoperative immunotherapy for mesothelioma shows favorable outcomes

by Dipali Pathak,Baylor College of MedicineCredit: Pixabay/CC0 Public DomainIn a study published recently in the journalClinical Cancer Research, researchers at Baylor College of Medicine

Updated on:January 04,2024

Lung nodule program provides benefits to patients ineligible for lung cancer screening

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainAdopting a lung nodule program (LNP) may increase the detection of early lung cancer for patients who are not

Updated on: December 30,2023

Lung nodule program provides benefits to patients ineligible for lung cancer screening

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainAdopting a lung nodule program (LNP) may increase the detection of early lung cancer for patients who are not

Updated on:December 30,2023

Radiation/cisplatin combination established as standard of care for HPV+ oral cancer

byAmerican Society for Radiation OncologyCombinations of radiation and chemotherapy drugs have been shown to cure HPV-related head and neck cancer with a high success rate. A new phase III trial

Updated on: December 18,2023

Radiation/cisplatin combination established as standard of care for HPV+ oral cancer

byAmerican Society for Radiation OncologyCombinations of radiation and chemotherapy drugs have been shown to cure HPV-related head and neck cancer with a high success rate. A new phase III trial

Updated on:December 18,2023

Study explores how antifragility in complex dynamical systems could revolutionize cancer treatment

byH. Lee Moffitt Cancer Center & Research InstituteAntifragility-associated terms, defined for technical and natural (biological) systems. Credit:npj Complexity(2024). DOI: 10.10

Updated on: August 26,2024

Study explores how antifragility in complex dynamical systems could revolutionize cancer treatment

byH. Lee Moffitt Cancer Center & Research InstituteAntifragility-associated terms, defined for technical and natural (biological) systems. Credit:npj Complexity(2024). DOI: 10.10

Updated on:August 26,2024

A silent killer, liver cancer prompts race to improve organ replacements

by Anthony King,Horizon: The EU Research & Innovation MagazineBioprinter from Organtrans. Credit: © Gilles WederWith the only cure for liver cancer often being a transplantation, scientists

Updated on: December 22,2023

A silent killer, liver cancer prompts race to improve organ replacements

by Anthony King,Horizon: The EU Research & Innovation MagazineBioprinter from Organtrans. Credit: © Gilles WederWith the only cure for liver cancer often being a transplantation, scientists

Updated on:December 22,2023

Quantitative pathologic analysis may help predict prognosis in colorectal cancer

The quantitative segmentation algorithm (QuantCRC) may improve the prediction of prognosis in colorectal cancer (CRC), according to a study published online Aug. 16 inGastroenterology.Reetesh K.

Updated on: December 20,2023

Quantitative pathologic analysis may help predict prognosis in colorectal cancer

The quantitative segmentation algorithm (QuantCRC) may improve the prediction of prognosis in colorectal cancer (CRC), according to a study published online Aug. 16 inGastroenterology.Reetesh K.

Updated on:December 20,2023

Scientists create an scRNA-seq atlas of the multiple myeloma immune microenvironment across disease stages

byVIB (the Flanders Institute for Biotechnology)The MM microenvironment is characterized by the presence of T cells with an exhausted phenotype. Credit:Journal of Hematology & Oncology

Updated on: December 02,2024

Scientists create an scRNA-seq atlas of the multiple myeloma immune microenvironment across disease stages

byVIB (the Flanders Institute for Biotechnology)The MM microenvironment is characterized by the presence of T cells with an exhausted phenotype. Credit:Journal of Hematology & Oncology

Updated on:December 02,2024